Pelvic Exenteration for Advanced Nonrectal Pelvic Malignancy

Conclusion: Pelvic exenteration remains an important treatment in selected patients with advanced or recurrent nonrectal pelvic malignancy. The range in 3-year overall survival following R0 resection (40%–59%) reflects the diversity of tumor types.
Source: Annals of Surgery - Category: Surgery Tags: ESA PAPERS Source Type: research